| The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses FK Föhse, B Geckin, GJ Overheul, J van de Maat, G Kilic, O Bulut, ... | 30 | 2021 |
| Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study RN Bouwmeester, C Duineveld, KL Wijnsma, FJ Bemelman, ... Kidney International Reports 8 (1), 91-102, 2023 | 20 | 2023 |
| Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria GAM Eliesen, J van Drongelen, PHH van den Broek, A Sarlea, ... British Journal of Clinical Pharmacology 87 (4), 2128-2131, 2021 | 7 | 2021 |
| The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment LP van den Heuvel, NCAJ van de Kar, C Duineveld, A Sarlea, ... Cellular & Molecular Immunology 17 (6), 653-655, 2020 | 6 | 2020 |
| MMR vaccination induces trained immunity via functional and metabolic reprogramming of γδ T cells RJ Röring, PA Debisarun, J Botey-Bataller, TK Suen, Ö Bulut, G Kilic, ... The Journal of Clinical Investigation 134 (7), 2024 | 3 | 2024 |
| MMR vaccination induces a trained immunity program characterized by functional and metabolic reprogramming of γδ T cells RJ Röring, PA Debisarun, J Botey-Bataller, TK Suen, Ö Bulut, G Kilic, ... bioRxiv, 2022.11. 24.516894, 2022 | 2 | 2022 |
| The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses (preprint) K Föhse, B Geckin, G Overheul, J van de Maat, G Kilic, O Bulut, H Dijkstra, ... | 1 | 2021 |
| Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans P Vuscan, B Kischkel, A Hatzioannou, E Markaki, A Sarlea, M Tintore, ... Frontiers in Immunology 15, 1323333, 2024 | | 2024 |
| Epigenetic Reprogramming Mediates Monocyte and Heterologous T Cell-derived Cytokine Responses after BCG Vaccination C Qi, Z Liu, G Kilic, AS Sarlea, PA Debisarun, X Liu, YA Mekonnen, W Li, ... medRxiv, 2024.03. 27.24304976, 2024 | | 2024 |
| ECULIZUMAB THERAPY MONITORING: RESIDUAL HEMOLYSIS IN ALTERNATIVE PATHWAY TEST IS NOT CAUSED BY C5 ACTIVITY B Van Den Heuvel, N Van De Kar, A Sarlea, S Van Kraaij, ... PEDIATRIC NEPHROLOGY 36 (10), 3288-3289, 2021 | | 2021 |
